Research on drug drug interactions with metabolism and brand names with some uses


  • Myle Akshay Kiran JNTU H


rug interactions are the harmful or beneficial effects of co administered medicinal products, these interaction may be synergistic or antogon istic pharmco kinetics or pharmaco dynamics, drug interactions exists between drugs anddrugs, drug and foods, drugs and herbs, benefits effects include convenience . Reduced toxicity and reduction.
When two or more drugs are administered concurrently or within a reasonable time or after each other (both prescription drugs and non prescription drugs are involved) , the result may be in difference, synergisim, potentation, antagonisim this is called AS .DRUG-DRUG INTRACTION. Drug metabolism interactions results in the increase of biological half life or reduction of clearance there requiring lower doses, imipramine reduces the clearance of epinephrine, some examples of the drugs that inhibit metabolism like Erythromycin, ketocanazole, fluxetin, cimitidine, Allopurinol , carbamazepine, phenobarbital, Rifampacin , and phenytoin. Risk of Therapeutic failure, stoppage of induced may lead to toxic concentration of substrate and induction may lead to formation of toxic metabolites.




Ancrenaz V, Daali Y, Fontana P et al. Impact of polymorphisms and drugdrug interacons on clopidogrel and prasugrel response variability . Curr Drug Metabo. 2010; 11:667-77.

Nguyen TA, Dioda JG, Pharand C. R esistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005; 45(8):1157-64.

Wang Y, Wang Y, Zhao X et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic a ack. N Engl J Med. 2013; 369:11-19.

Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral an-

plat elet therapy following percutaneous coronary intervenon: a random -

ized controlled trial. J Am Med Assoc. 2002; 288(19):2411-20.

Yusuf S, Zhao F, Mehta SR et al. E ects of clopidogrel in addion t o aspirin in paen ts with acute coronary syndromes without ST-segment elevaon. N Engl J Med. 2001; 345(7):494-502.

Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three an -

thrombic-drug regimens a er coronary-artery stenng. N E ngl J Med. 1998; 339(23):1665-71.

Bha DL , Scheiman J, Abraham NS et al. ACCF/ACG/AHA Expert consensus document on reducing the gastrointesnal risk s of anplat elet therapy and NSAID use. J Am Coll Cardiol. 2008; 52(18):1502-17.

Gilard M, Arnaud B, Cornily JC et al. Inuenc e of omeprazole on the an -

platelet acon of clopidogrel associat ed with aspirin. J Am Coll Cardiol. 2008; 51(3):256-60.

Juurlink DN, Gomes T, Ko DT et al. A populaon-based s tudy of the drug interacon be tween proton pump inhibitors and clopidogrel. Can Med Assoc J. 2009; 180(7):713-8.

Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J Am Med Assoc. 2009; 301(9):937-44.

Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitor on the anplat elet e ects of clopidogrel. Throm Haemost. 2009; 101(4):714-9. 12. Siller-Matula JM, Spiel AO, Lang IM et al. E ects of pantoprazole and esomeprazole on platelet inhibion b y clopidogrel. Am Heart J. 2009; 157(1):148e1-e5.

Dunn SP, Steinhubl SR, Bauer D et al. Impact of proton pump inhibitor therapy on the ec acy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc. 2013; 2(1):e004564

Kowk CS, Loke YK. Meta-analysis: the e ects of proton pump inhibitors on cardiovascular events and mortality in paen ts receiving clopidogrel. Aliment Pharmacol Ther. 2000; 14:1191-98 15. Naonal Choles terol Educaon Program (NCEP) Expert P anel on Detec-

on, E valuaon, and T reatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the Naonal Choles terol Educaon Program (NCEP) Expert Panel on Detecon, E valuaon, and T reatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) nal report. Circulaon. 2002;106(25):3143-421.

Food-Drug Interactions

Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr Opin Lipidol. 2013;24(3):239-45. 17. Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol. 2012;32(3):582-8.

Villines TC, Kim AS, Gore RS et al. Niacin: the evidence, clinical use, and future direcons. Curr A theroscler Rep. 2012;14(1):49-59. 19. HPS2-THRIVE Collaborave Group. HPS2-THRIVE random -

ized placebo-controlled trial in 25 673 high-risk paen ts of ER niacin/laropiprant: trial design, pre-specied muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279-91.

Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athero-

scleroc Cardio vascular Risk in Adults: A Report of the American College of Cardiology/American Heart Associaon T ask Force on Pracc e Guidelines. Circulaon. 2013[epub ahead of prin t]. 21. Pieper JA. Overview of niacin formulaons: di erences in pharmacokinecs, e c acy, and safety. Am J Health Syst Pharm. 2003;60(13 Suppl 2):S9-14;quiz S25.

Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. 2007;11(3):597-613, vii. 23. McKenney J. Niacin for dyslipidemia: consideraons in product selecon. Am J Health S yst Pharm. 2003;60(10):995-1005.

Kelley VE, Fere A , Izui S et al. A sh oil die t rich in eicosapen-

taenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in mrl-lpr mice. J Immunol. 1985; 134(3):1914-19.

Kar S, Webel R. Fish oil supplementaon and c oronary artery disease: does it help? Mo Med. 2012; 109(2):141-5.

Weitz D, Weintraub H, Fisher E et al. Fish oil for the treatment of cardiovascular disease. Cardiol Rev. 2010; 18(5):258-69.

Shahar E, Folsom AR, Dennis BH et al. Associaon of sh in take and dietary n-3 polyunsaturated fay acids with a h ypocoagula-

ble prole. The atherosclerosis risk in c ommunies (ARIC) s tudy. Arterioscler Thromb Vasc Biol. 1993; 13: 1205-12.

Kim DN, Eastman A, Baker JE et al. Fish oils, atherogenesis, and thrombogenesis. Ann N Y Acad Sci. 1995; 748:474-80.

Kaminski WE, Jendraschak E, Kie R e t al. Dietary omega-3 fay acids lo wer levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood. 1993; 81:1871-9.

Mayer K, Merfels M, Muhly-Reinholz M et al. Omega-3 fay

acids suppress monocyte adhesion to human endothelial cells: role

of endothelial PAF generaon. Am J Ph ysio Heart Circ Physiol. 2002; 283:H811-8.

Buckley MS, Go AD , Knapp WE. Fish oil interacon with war -

farin. Ann Pharmacother. 2004; 38:50-3.

Eritsland J, Arnesen H, Seljeot I e t al. Long-term e ects of n-3 polyunsaturated fay acids on haemos tac variables and bleeding episodes in paen ts with coronary artery disease. Blood Coagul Fibrinolysis. 1995; 6:17-22

Bender NK, Kraynak MA, Chique e E et al. E ects of marine sh oils on the an c oagulaon s tatus of paen ts receiving chronic warfarin therapy. J Thromb Thrombolysis. 1998; 5:257-61.

Bays HE. Safety consideraons with omega-3 f ay acid thera -

py. Am J Cardiol. 2007; 99:35C-43C.

Fung WT, Subramaniam G, Lee J et al. Assessment of extracts from red yeast rice for herb-drug interacon b y in-vitro and in-vivo assays. Sci Rep. 2012;2:298.

Gordon RY, Becker DJ. The role of red yeast rice for the physi-

cian. Curr Atheroscler Rep. 2011;13(1):73-80.

Childress L, Gay A, Zargar A et al. Review of red yeast rice content and current Food and Drug Administraon o versight. J Clin Lipidol. 2013;7(2):117-22

Klimek M, Wang S, Ogunkanmi A. Safety and ec acy of redyeast rice (Monascus purpureus) as an alternave therap y for hyperlip-

idemia. P T. 2009;34(6):313-27.

Chen CH, Uang YS et al. Interacon be tween Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implicaon f or the clinical pharmacokinecs of lo vastan. E vid Based Complement Alternat Med.2012;2012:127043.

European Associaon f or Cardiovascular Prevenon & R ehabili-

taon, R einer Z,Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the man-

agement of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818.

Heber D, Lembertas A, Lu QY et al. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implicaons of vari -

ability in chemical prole and c ontents. J Altern Complement Med. 2001;7(2):133-9.

Gordon RY, Cooperman T, Obermeyer W et al. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722-7.

Ernst E. The risk-benet prole of c ommonly used herbal therapies: Ginkgo, St. John’s Wort, Ginseng, Echinacea, Saw Palme o, and Kava. Ann Intern Med. 2002;136(1):42-53. Review.

Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev. 2008; (4):CD000448.Review.

Shelton RC, Keller MB, Gelenberg A et al. E ecveness of St John’ s wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978-86.

Hypericum Depression Trial Study Group. E ect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA.2002;287(14):1807-14.

American Psychiatric Associaon. Pracc e Guideline for the Treatment of Paen ts With Major Depressive Disorder, Third Edi-

on. h p://p -

id=1667485#654006. (accessed 2014 Jan 20).

Benne D A Jr, Phun L, Polk JF et al. Neuropharmacology of St. John’s Wort (Hypericum). Ann Pharmacother. 1998;32(11):1201-8. Review. 49. Müller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmi er reuptake inhibing c onstuen t of hypericum extract. Ph



How to Cite

Akshay Kiran, M. (2017). Research on drug drug interactions with metabolism and brand names with some uses. Innovare Journal of Medical Sciences, 5(5), 3–7. Retrieved from



Review Article(s)